At present, many studies have shown patients with high TMB in tumors have a better therapeutic effect on anti-PD-1/PD-L1 immunotherapy (47, 48), and the same is true for NSCLC patients (49). The gene discussed is CD274; the disease is non-small cell lung carcinoma.